Arm Morbidity Higher with Extensive Lymph Node Surgery in Younger Patients with Breast Cancer

JHOP - December 2017 Vol 7, No 4 - Breast Cancer

Arm morbidity is frequently observed after surgery for breast cancer, but can have a greater detrimental impact on younger women “given their long survivorship period, frequently active lifestyle, and the importance of body image,” said Anne Kuijer, PhD, a postdoctoral research fellow at Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Boston, MA. “These issues are of particular importance in these patients.”

Severe arm morbidity is less common than it once was with a movement toward sentinel lymph node biopsy (SLNB) and away from axillary lymph node dissection (ALND), which can cause extensive swelling in the arm due to surgery to remove lymph nodes (lymphedema). The rate of lymphedema is about 20% and the rate of shoulder impairment can be as high as 28% as late effects following axillary surgery. However, these problems have not been studied specifically in younger women.

To assess the incidence of arm morbidity associated with ALND and SLNB, Dr Kuijer and colleagues examined 10 years of reports (2006-2016) from 1302 women aged ≤40 years who were enrolled in the Young Women’s Breast Cancer Study. Fifty-five percent of the women had undergone an SLNB only and 41% had undergone ALND. In 4% of patients, no axillary surgery was performed.

The investigators examined the incidence of patient-reported arm swelling or decreased range of motion 1 year after diagnosis. Overall, 13% reported arm swelling and 40% reported decreased range of motion in the ipsilateral arm—the arm on the same side as the breast tumor—1 year after their breast cancer diagnosis.

Among the patients who were treated with breast-conserving surgery, the incidence of arm swelling 1 year after diagnosis was 6% in patients who underwent SLNB and 24% in those who received ALND. For patients who underwent unilateral or bilateral mastectomy, the incidence of arm swelling was 6% in the SLNB group and 23% in the ALND group.

Among the women who underwent breast-conserving surgery, the rate of decreased range of motion in the ipsilateral arm was 32% and 36% in patients who underwent SLNB or ALND, respectively. Among those who underwent unilateral or bilateral mastectomy with SLNB or ALND, these rates were 28% and 44%, respectively.

Certain patient factors were associated with greater risk of arm morbidity. For example, being overweight at the time of diagnosis increased the risk for arm swelling and decreased range of motion. In addition, women who described themselves as financially comfortable were less likely to develop arm swelling.

Dr Kuijer said that because the study included women who were treated at large cancer centers in the Northeast, and thus were likely to have a high socioeconomic status, the incidence of arm morbidity may be even higher in the general population.

The findings highlight the importance of de-escalating axillary treatment when appropriate in young patients with breast cancer, and illustrates that even conservative surgery has long-lasting effects. “Women should be encouraged to talk to their doctors about all of their options for surgery and the expected outcomes,” Dr Kuijer concluded.

Source:
Kuijer A, Dominici LS, Rosenberg SM, et al. Risk of arm morbidity after local therapy in young breast cancer survivors. Presented at: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017. Abstract GS5-03.

Related Items
Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
JHOP Web Exclusives published on April 7, 2018 in Breast Cancer, Online Only
Taselisib, a PI3K Inhibitor, Shrinks Tumors in Early Breast Cancer, with Added Activity in Patients with PI3KCA Mutation
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Breast Cancer
Blood-Based Biopsy Can Predict Breast Cancer Recurrence
TON Web Exclusives published on February 26, 2018 in Breast Cancer
The Benefit of CDK4/6 Inhibitors Applies Equally to Older Women with Breast Cancer
TON Web Exclusives published on February 26, 2018 in Breast Cancer
Immunotherapy Continues to Gain Momentum in Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
Dose-Intense Chemotherapy Shown to Improve Outcomes in Patients with Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
Long-Term Data from the TEAM Trial Support Individualized Adjuvant Endocrine Therapy Strategy for Postmenopausal Women with HR-Positive Early Breast Cancer
TON Web Exclusives published on December 28, 2017 in Breast Cancer
Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2
TON Web Exclusives published on December 28, 2017 in Breast Cancer
Results of DATA Study Failed to Show Benefits for Extended Endocrine Therapy in Women with Breast Cancer
TON Web Exclusives published on December 28, 2017 in Breast Cancer
BRCA1/2 Status Affects Response to Polychemotherapy in Triple-Negative Breast Cancer
TON Web Exclusives published on December 28, 2017 in Breast Cancer
Last modified: February 26, 2018